Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expandi...
31 Mai 2016 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an
oncology-focused biotechnology company, today announces that the
United States Patent and Trademark Office (“USPTO”) has issued U.S.
Patent No. 9,339,564, which covers the treatment of cancer stem
cells employing the company’s phospholipid drug conjugate (“PDC”)
delivery platform technology; specifically, either of the company’s
current PDC products, CLR 131 or CLR 125, in combination with
external beam radiation. This patent, which provides intellectual
property protection to at least June 2030, is based on one of
multiple patent applications directed to the treatment of cancer
stem cells.
The company’s radioiodinated compounds may possess the unique
ability to target and potentially kill both cancer and cancer stem
cells while sparing healthy cells and normal stem cells. Cancer
stem cells are known to be highly resistant to traditional
chemotherapeutics and potentially a significant source of
metastasis. Beyond traditional chemotherapeutics, cancer stem cells
have been shown to be as much as 30 percent more radioresistant
than cancer cells, further increasing the challenge of treating
cancer.
“The recent USPTO actions have expanded and strengthened
Cellectar’s intellectual property portfolio for strategic PDC
program assets, including our radiotherapeutics in combination with
external beam radiation in a wide range of cancers,” said Jim
Caruso, president and CEO of Cellectar. “Importantly, they also
provide yet another clear example of the broad utility and
potential of our delivery platform. The company will continue its
aggressive approach to protect assets and increase their respective
value, whether internally or collaboratively developed.”
This patent, which describes the combined use of either CLR 131
or CLR 125 with external beam radiotherapy, utilizes the unique
targeted delivery property of PDCs to internally supplement the
radiation dose to the entire tumor and specifically cancer stem
cells. The cancer stem cells then become as radiosensitive as other
cancer cells. If successful, this dual internal-external
radiotherapy approach may achieve a more effective and durable
treatment response.
John S. Kuo, MD, PhD, FAANS, FACS, Associate Professor of
Neurological Surgery and Human Oncology (Tenure) Director,
Comprehensive Brain Tumor Program Chair, CNS Tumors Working Group,
Carbone Cancer Center, Center for Stem Cell and Regenerative
Medicine at the University of Wisconsin-Madison, added: “Our
studies conducted to date at the Carbone Cancer Center demonstrate
that Cellectar’s PDC delivery vehicle, a proprietary phospholipid
ether analog, also targets therapy-resistant cancer stem cells
responsible for cancer growth and recurrence. PDCs show promise as
a means of targeting and treating all of the tumor cells within a
patient’s cancer, including cancer stem cells.”
About Phospholipid Drug Conjugates (PDCs)
The foundation of Cellectar’s delivery platform technology is
its proprietary, small molecule, phospholipid ether cancer
targeting drug vehicle. The drug vehicle preferentially
delivers cytotoxic compounds directly to cancer cells, thus
limiting the drug’s impact on healthy cells, increasing the potency
of the drug at lower concentrations and improving the compound’s
adverse event profile. Cellectar’s PDC platform has demonstrated
highly selective cancer targeting both preclinically in over 60 in
vivo cancer models, and subsequently confirmed clinically in over
10 cancer types. The platform's payload diversity has been
validated using cytotoxic radioisotopes for cancer therapy, PET
imaging isotopes for cancer imaging, and fluorophores for
image-guided surgery. Recently, the company has expanded its
payload portfolio to chemotherapeutics with further research of
paclitaxel and other non-targeted anti-cancer agents through both
in-house and collaborative R&D efforts.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC Delivery Platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules
have demonstrated highly selective uptake and retention in a broad
range of cancers. Cellectar's PDC pipeline includes product
candidates for cancer therapy and cancer diagnostic imaging. The
company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a
cytotoxic radioisotope, as its payload. CLR 131 is currently being
evaluated under an orphan drug designated Phase 1 study in patients
with relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1603-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form 10-K
for the year ended December 31, 2015. These forward-looking
statements are made only as of the date hereof, and we disclaim any
obligation to update any such forward-looking statements.
INVESTOR AND MEDIA CONTACT:
Jules Abraham JQA Partners 917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024